News and Trends 24 Mar 2017 Novartis puts the Development of two Anti-Aging Drugs in American Hands PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […] March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 24 Mar 2017 This Swedish Biotech Uses Bacteria to Treat Diseases in Infants This week’s biotech brought us to Scandinavia. Based in Sweden’s capital, Stockholm, Infant Bacterial Therapeutics aims to treat rare diseases affecting newborns by targeting the infant microbiome. Mission: Infant Bacterial Therapeutics (IBT) aims to treat rare diseases affecting infants for which there is currently no treatment available. The company makes use of live bacterial therapeutics, which modulate inflammatory […] March 24, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2017 New Biochips Quickly Identify the Best Antibiotic for each Bacterial Infection Scientists from Israel have piloted a new silicon biosensor chip that can rapidly identify the best antibiotics for treating a bacterial infection. Antibiotic resistance makes up one of the major health challenges of the 21st century. Some of the major causes of the increasing numbers of resistant bacterial strains are overuse of antibiotics and mistreatment of infections. […] March 24, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 A Cheaper Heat-Stable Vaccine Could Prevent Child Deaths in Africa An innovative rotavirus vaccine, BRV-PV, which does not require refrigeration, has passed Phase III trials in children living in sub-Saharan Africa. The Research and Epidemiology branch of the humanitarian organization Doctors without Borders (MSF), Epicentre, has published the results of its recent Phase III trial for a new oral vaccine against rotavirus infection. The vaccine, […] March 23, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […] March 23, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 23 Mar 2017 Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […] March 23, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2017 Speed up R&D? Eppendorf is Offering a new Solution! With their latest bioreactor system, BioFlo 120, Eppendorf is aiming to make bioprocesses more flexible and straightforward. Apart from brewing beer, bioprocesses play a major role in the biotech industry. Ever since the breakthrough of genetic engineering technologies in the end of the last century, we have started to exploit microorganisms or mammalian cells as […] March 23, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2017 Swedish Oncology Biotech Teams up with World Leading Cancer Center The Swedish biotech Aprea Therapeutics has entered a new collaboration with the Memorial Sloan Kettering Cancer Center to study the effects of its lead APR-246. Based in Stockholm, Aprea therapeutics is focusing on the development of its only drug candidate, APR-246. The molecule targets the key tumor supressor p53 to restore its function. Now, in collaboration […] March 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2017 France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies With its new Fund for Innovation, Pierre Fabre will collaborate with H-Immune to use its ‘In Vitro Immunization’ (IVI) platform for the development of fully human monoclonal antibodies (mAbs). Pierre Fabre is the 2nd largest private pharmaceutical company in France and has recently made efforts to open up its innovation process. Since the establishment of the Pierre […] March 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 22 Mar 2017 Watch a Partner at Spain’s Largest VC talk Investment Strategy At BIO Europe Spring, we met Karen Wagner, a General Partner at Ysios, the VC dominating Spain’s investment scene. She told us what’s on the firm’s radar. Spain’s largest VC has positioned itself in Barcelona, having identified the city’s potential to be the next biotech hub in Europe. It has funded key biotechs in Spain, including Sanifit, which claimed the […] March 22, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2017 What’s the Gold Standard for Therapeutic Antibodies? Are fully human antibodies the new gold standard in therapeutic innovation? If you want to upgrade, here’s where to find them. If you’re curious about the future of antibody development, look no further than Humira. This monoclonal antibody (mAb) for various inflammatory diseases soared to become the best-selling biological in 2016. Humira is a fully human […] March 22, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2017 A Potential First Treatment for a Rare Genetic Disease clears Phase I Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […] March 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email